LDN-214117

Bone morphogenetic proteins (BMPs) are secreted signaling proteins, many of which are involved in various developmental processes, in addition to bone formation. Activation of BMP type I receptors, also known as activin receptor-like kinases (ALK1-7), leads to the assembly of SMAD complexes, which translocate to the nucleus to induce transcriptional activation important for normal development and tissue repair. LDN-214117 is a selective BMP type I receptor kinase ALK1 and ALK2 inhibitor (IC50s = 24 nM for each). It demonstrates preference for ALK1 and ALK2 over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-beta type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-beta, respectively).Formal Name: 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl]-piperazine. CAS Number: 1627503-67-6. Molecular Formula: C25H29N3O3. Formula Weight: 419.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/mL, DMF:PBS(pH 7.2)(1:1): 0.5 mg/mL, DMSO: 25 mg/mL, Ethanol: 25 mg/mL. lambdamax: 300 nm. SMILES: COC1=C(OC)C(OC)=CC(C2=C(C)N=CC(C3=CC=C(N4CCNCC4)C=C3)=C2)=C1. InChi Code: InChI=1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3. InChi Key: BHUXVRVMMYAXKN-UHFFFAOYSA-N.